Cumberland Pharmaceuticals 3Q 2026: Revenue $2.16M, EPS $5.07 — 10-Q Summary
Cumberland Pharmaceuticals reported 3Q 2026 revenue of $2.16M, up 1155% YoY, driven by transition services revenue. Net income was $77.78M, swinging to profit from a loss, with EPS at $5.07. The company completed a $100M Apotex transaction and is advancing its Ifetroban pipeline.
How this was made

The 30-second read
Why it matters
The surprise profit could trigger a short‑term rally, but investors should assess the durability of the underlying business.
Market read
Earnings surprise for a micro‑cap biotech; may attract speculative buying.
What to watch
Sustaining revenue after the Apotex transaction remains uncertain; pipeline progress is still early.
Background
Cumberland Pharmaceuticals filed its Q3 2026 10‑Q, showing a dramatic earnings swing after a $100M Apotex sale and a disposal gain.
Ticker impact
Cumberland Pharmaceuticals reported Q3 2026 revenue of $2.16M and a surprise profit of $77.78M in its 10‑Q filing.
upward pressure as market prices in the unexpected profit and revenue growth.
The company posted a large profit swing from a loss, driven by a $81.1M disposal gain and higher interest income, which is material for a micro‑cap.
Market effects
Highlights potential upside for small‑cap pharma stocks with asset disposals and transaction‑driven revenue.
Limited to U.S. micro‑cap biotech segment.
Low global relevance; primarily affects niche investors.
Counterpoint
The profit is largely one‑off from asset disposal; future earnings may revert to loss.
Key entities
- CompanyCumberland Pharmaceuticals
Micro‑cap pharma firm reporting Q3 2026 results.

